BECN1

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease

Retrieved on: 
Thursday, April 11, 2024
UNC, Doctor of Philosophy, BECN1, Autophagy, ERK, Pathology, HGF, AKT, Athira Pharma, Alzheimer's disease, Disease, Excitotoxicity, Toxicity, Shikimate pathway, ULK1

The original research article, “ Fosgonimeton Attenuates Amyloid-Beta Toxicity in Preclinical Models of Alzheimer’s Disease ,” authored by Reda, S., et al., was published in the peer-reviewed journal, Neurotherapeutics.

Key Points: 
  • The original research article, “ Fosgonimeton Attenuates Amyloid-Beta Toxicity in Preclinical Models of Alzheimer’s Disease ,” authored by Reda, S., et al., was published in the peer-reviewed journal, Neurotherapeutics.
  • “These data continue to highlight the potential of fosgonimeton as a novel therapeutic approach for Alzheimer's disease targeting multiple facets of its complex pathophysiology,” said Kevin Church, Ph.D., Chief Scientific Officer of Athira.
  • “These preclinical data published in a peer-reviewed journal suggest that fosgonimeton counteracts aspects of AD pathology that lead to neurodegeneration.
  • These findings bolster our confidence in the Phase 2/3 LIFT-AD trial evaluating fosgonimeton in mild-to-moderate AD, with data anticipated in the second half of 2024.”